JP2005529913A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005529913A5 JP2005529913A5 JP2004503001A JP2004503001A JP2005529913A5 JP 2005529913 A5 JP2005529913 A5 JP 2005529913A5 JP 2004503001 A JP2004503001 A JP 2004503001A JP 2004503001 A JP2004503001 A JP 2004503001A JP 2005529913 A5 JP2005529913 A5 JP 2005529913A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- valeryl
- syndrome
- platelet aggregation
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ICSQZMPILLPFKC-XLDIYJRPSA-N 4-Hydroxyvalsartan Chemical compound C1=CC(CN(C(=O)CCC(O)C)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ICSQZMPILLPFKC-XLDIYJRPSA-N 0.000 claims description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 239000002207 metabolite Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 206010003178 Arterial thrombosis Diseases 0.000 claims 2
- 206010008479 Chest Pain Diseases 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010038563 Reocclusion Diseases 0.000 claims 1
- 206010062546 Thrombosis in device Diseases 0.000 claims 1
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037765 diseases and disorders Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 6
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 6
- 229960004699 valsartan Drugs 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000013166 platelet test Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38037302P | 2002-05-14 | 2002-05-14 | |
| US39501402P | 2002-07-11 | 2002-07-11 | |
| PCT/EP2003/004997 WO2003094915A1 (en) | 2002-05-14 | 2003-05-13 | Use of valsartan ot its metabolite to inhibit platelet aggregation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005529913A JP2005529913A (ja) | 2005-10-06 |
| JP2005529913A5 true JP2005529913A5 (https=) | 2006-06-22 |
| JP4467427B2 JP4467427B2 (ja) | 2010-05-26 |
Family
ID=29423705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004503001A Expired - Lifetime JP4467427B2 (ja) | 2002-05-14 | 2003-05-13 | 血小板凝集を阻害するためのバルサルタンまたはその代謝物の使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20050197372A1 (https=) |
| EP (1) | EP1505965B1 (https=) |
| JP (1) | JP4467427B2 (https=) |
| KR (1) | KR101005367B1 (https=) |
| CN (1) | CN100408035C (https=) |
| AT (1) | ATE334677T1 (https=) |
| AU (1) | AU2003267447B8 (https=) |
| BR (1) | BR0310018A (https=) |
| CA (1) | CA2482541A1 (https=) |
| CY (1) | CY1105638T1 (https=) |
| DE (1) | DE60307265T2 (https=) |
| DK (1) | DK1505965T3 (https=) |
| ES (1) | ES2268403T3 (https=) |
| IL (2) | IL164774A0 (https=) |
| MX (1) | MXPA04011282A (https=) |
| NO (1) | NO20045245L (https=) |
| NZ (1) | NZ536295A (https=) |
| PL (1) | PL371728A1 (https=) |
| PT (1) | PT1505965E (https=) |
| RU (1) | RU2334512C2 (https=) |
| TW (1) | TWI299663B (https=) |
| WO (1) | WO2003094915A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| TW200523257A (en) * | 2003-09-26 | 2005-07-16 | Novartis Ag | Use of organic compounds |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| AR068814A1 (es) * | 2007-08-29 | 2009-12-09 | Orion Corp | Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso |
| RU2410104C1 (ru) * | 2009-07-10 | 2011-01-27 | Учреждение Российской академии медицинских наук Научный центр неврологии РАМН | СПОСОБ СНИЖЕНИЯ АГРЕГАЦИОННОЙ АКТИВНОСТИ ТРОМБОЦИТОВ in vitro |
| US10478404B2 (en) | 2014-01-24 | 2019-11-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Materials, methods and devices for altering cell reactivity |
| CN110078640B (zh) * | 2019-03-29 | 2022-04-05 | 浙江美诺华药物化学有限公司 | 一种缬沙坦中间体的合成方法 |
| CN111643557B (zh) * | 2020-05-26 | 2022-02-22 | 四川省骨科医院 | 一种防治下肢深静脉血栓后遗症期的药物组合物及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE312198T1 (de) * | 1993-04-05 | 2005-12-15 | Univ Utah Res Found | Diagnose und behandlung von supravalvular aortic stenosis |
| US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| CA2379666C (en) * | 1999-07-21 | 2009-10-13 | Takeda Chemical Industries, Ltd. | Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof |
| AU2001267404A1 (en) * | 2000-05-04 | 2001-11-12 | Ipf Pharmaceuticals Gmbh | Novel compounds for the treatment of inflammatory and cardiovascular diseases |
| NZ522953A (en) * | 2000-06-22 | 2005-10-28 | Novartis Ag | Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate |
-
2003
- 2003-05-12 TW TW092112854A patent/TWI299663B/zh not_active IP Right Cessation
- 2003-05-13 IL IL16477403A patent/IL164774A0/xx unknown
- 2003-05-13 AU AU2003267447A patent/AU2003267447B8/en not_active Ceased
- 2003-05-13 MX MXPA04011282A patent/MXPA04011282A/es active IP Right Grant
- 2003-05-13 WO PCT/EP2003/004997 patent/WO2003094915A1/en not_active Ceased
- 2003-05-13 DK DK03749892T patent/DK1505965T3/da active
- 2003-05-13 ES ES03749892T patent/ES2268403T3/es not_active Expired - Lifetime
- 2003-05-13 CA CA002482541A patent/CA2482541A1/en not_active Abandoned
- 2003-05-13 CN CNB03810864XA patent/CN100408035C/zh not_active Expired - Fee Related
- 2003-05-13 EP EP03749892A patent/EP1505965B1/en not_active Expired - Lifetime
- 2003-05-13 RU RU2004136583/15A patent/RU2334512C2/ru not_active IP Right Cessation
- 2003-05-13 BR BR0310018-9A patent/BR0310018A/pt not_active IP Right Cessation
- 2003-05-13 US US10/514,299 patent/US20050197372A1/en not_active Abandoned
- 2003-05-13 KR KR1020047018282A patent/KR101005367B1/ko not_active Expired - Fee Related
- 2003-05-13 AT AT03749892T patent/ATE334677T1/de active
- 2003-05-13 PT PT03749892T patent/PT1505965E/pt unknown
- 2003-05-13 DE DE60307265T patent/DE60307265T2/de not_active Expired - Lifetime
- 2003-05-13 NZ NZ536295A patent/NZ536295A/en not_active IP Right Cessation
- 2003-05-13 PL PL03371728A patent/PL371728A1/xx unknown
- 2003-05-13 JP JP2004503001A patent/JP4467427B2/ja not_active Expired - Lifetime
-
2004
- 2004-10-21 IL IL164774A patent/IL164774A/en not_active IP Right Cessation
- 2004-11-30 NO NO20045245A patent/NO20045245L/no not_active Application Discontinuation
-
2006
- 2006-09-28 CY CY20061101409T patent/CY1105638T1/el unknown
-
2009
- 2009-02-02 US US12/363,926 patent/US20100048654A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Erley et al. | Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs. | |
| CAMPBELL JR et al. | Ascorbic acid-induced hemolysis in G-6-PD deficiency | |
| Flynn et al. | A randomized, placebo-controlled trial of amlodipine in children with hypertension | |
| Mandell et al. | Histoplasmosis in patients with the acquired immune deficiency syndrome | |
| Bristow et al. | Early anthracycline cardiotoxicity | |
| Swanson et al. | Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia | |
| Ha et al. | Platelet aggregability in vivo is attenuated byverapamil but not bymetoprolol in patients with stable angina pectoris | |
| Waller | Early and late morphologic changes in human coronary arteries after percutaneous transluminal coronary angioplasty | |
| Hall et al. | Sequential treatment with quinine and mefloquine or quinine and pyrimethamine-sulfadoxine for falciparum malaria. | |
| Yale et al. | Bronchiolitis obliterans organizing pneumonia caused by Plasmodium vivax malaria | |
| JP2005529913A5 (https=) | ||
| Snyder et al. | COMPARATIVE EFFICACY OF CHLORAMPHENICOL, AMPICILLIN, AND CO-TRIMOXAZOLE IN THE TREATMENT OF | |
| Dollery et al. | Dose and concentration-effect relations for rilmenidine | |
| Graafsma et al. | Digoxin toxicity with therapeutic serum digoxin concentrations | |
| Sauer | Recurrent embolic stroke and cocaine-related cardiomyopathy. | |
| Patel et al. | Profound thrombocytopenia associated with tirofiban: case report and review of literature | |
| JPS62185014A (ja) | 複合調剤薬 | |
| RU2542455C2 (ru) | Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек | |
| Massarella et al. | The effect of probenecid on the pharmacokinetics of zalcitabine in HIV-positive patients | |
| Ikeda et al. | Diffuse alveolar hemorrhage as a complication of dual antiplatelet therapy for acute coronary syndrome | |
| GREENE et al. | Trimethoprim-sulfamethoxazole and brain abscess | |
| JP2022535602A (ja) | 心血管有害事象のリスクのある対象における鉄欠乏症の処置 | |
| Hornum et al. | Felodipine and renal function in lung transplantation: A randomized placebo-controlled trial | |
| FINLAYSON et al. | Hypercalcaemia and multiple Pheochrcmocytomas | |
| NZ525487A (en) | Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders |